HC Wainwright Comments on Mural Oncology Q3 Earnings

Mural Oncology plc (NASDAQ:MURA - Free Report) - Stock analysts at HC Wainwright issued their Q3 2024 earnings per share (EPS) estimates for shares of Mural Oncology in a report released on Thursday, October 17th. HC Wainwright analyst A. Maldonado expects that the company will post earnings per share of ($2.06) for the quarter. HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for Mural Oncology's current full-year earnings is ($7.47) per share. HC Wainwright also issued estimates for Mural Oncology's Q4 2024 earnings at ($2.09) EPS, FY2024 earnings at ($7.85) EPS, Q1 2025 earnings at ($2.12) EPS, Q2 2025 earnings at ($1.45) EPS, Q3 2025 earnings at ($1.47) EPS, Q4 2025 earnings at ($1.48) EPS, FY2025 earnings at ($6.52) EPS, FY2026 earnings at ($4.56) EPS, FY2027 earnings at ($3.09) EPS and FY2028 earnings at ($2.41) EPS.

Mural Oncology (NASDAQ:MURA - Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($1.86) EPS for the quarter, beating the consensus estimate of ($1.90) by $0.04.

Several other research analysts also recently weighed in on the company. Raymond James initiated coverage on Mural Oncology in a research note on Friday, October 4th. They set a "strong-buy" rating and a $18.00 target price for the company. Rodman & Renshaw began coverage on shares of Mural Oncology in a research report on Friday, June 28th. They issued a "buy" rating and a $15.00 target price on the stock.

Mural Oncology Price Performance

NASDAQ MURA traded up $0.01 during trading hours on Monday, reaching $3.66. The company's stock had a trading volume of 55,010 shares, compared to its average volume of 189,666. Mural Oncology has a 1-year low of $2.88 and a 1-year high of $17.00. The company's 50-day moving average is $3.28 and its two-hundred day moving average is $3.43. The firm has a market capitalization of $61.94 million and a price-to-earnings ratio of -0.35.

Institutional Trading of Mural Oncology

Several large investors have recently made changes to their positions in MURA. Acadian Asset Management LLC acquired a new stake in Mural Oncology during the 2nd quarter worth $998,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Mural Oncology in the second quarter worth about $84,000. Armistice Capital LLC acquired a new position in Mural Oncology during the second quarter worth about $5,300,000. Primecap Management Co. CA purchased a new stake in Mural Oncology during the 2nd quarter valued at about $740,000. Finally, Canada Pension Plan Investment Board purchased a new stake in Mural Oncology during the 2nd quarter valued at about $70,000. 80.21% of the stock is currently owned by hedge funds and other institutional investors.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.